BMJ Rapid Recommendations: PCSK9-inhbititors, ezetimibe and statins to reduce cardiovascular risk

Published by Qiukui Hao on May 5, 2022

View

Disclaimer

Sponsors

Contact

Abstract

Language

en

PICOS

PICO 10.1

Population
Adults in secondary prevention receiving high dose statins and considering further CV risk reduction (very high risk)
Intervention
Ezetimibe plus statins
Comparator
Statins
Outcomes

PICO 10.2

Population
Adults in secondary prevention receiving high dose statins and considering further CV risk reduction (very high risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus statins
Comparator
Statins
Outcomes

PICO 10.3

Population
Adults in secondary prevention receiving high dose statins and considering further CV risk reduction (very high risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus statins
Comparator
Ezetimibe plus statins
Outcomes

PICO 10.4

Population
Adults in secondary prevention receiving high dose statins and considering further CV risk reduction (very high risk)
Intervention
Ezetimibe adding to PCSK9 and statins
Comparator
PCSK9 and statins
Outcomes

PICO 10.5

Population
Adults in secondary prevention receiving high dose statins and considering further CV risk reduction (very high risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus statins and ezetimibe
Comparator
Statins and ezetimibe
Outcomes

PICO 10.6

Population
Adults in secondary prevention intolerant to statins and considering further CV risk reduction (very high risk)
Intervention
Ezetimibe
Comparator
No lipid-lowering drug
Outcomes

PICO 10.7

Population
Adults in secondary prevention intolerant to statins and considering further CV risk reduction (very high risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors
Comparator
No lipid-lowering drug
Outcomes

PICO 10.8

Population
Adults in secondary prevention intolerant to statins and considering further CV risk reduction (very high risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors
Comparator
Ezetimibe
Outcomes

PICO 10.9

Population
Adults in secondary prevention intolerant to statins and considering further CV risk reduction (very high risk)
Intervention
Ezetimibe and PCSK9 inhibitors
Comparator
PCSK9 inhibitors
Outcomes

PICO 10.10

Population
Adults in secondary prevention intolerant to statins and considering further CV risk reduction (very high risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus ezetimibe
Comparator
Ezetimibe
Outcomes

PICO 10.11

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (high risk)
Intervention
Ezetimibe plus statins
Comparator
Statins
Outcomes

PICO 10.12

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (high risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus statins
Comparator
Statins
Outcomes

PICO 10.13

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (high risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus statins
Comparator
Ezetimibe plus statins
Outcomes

PICO 10.14

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (high risk)
Intervention
Ezetimibe and PCSK9 and statins
Comparator
PCSK9 and statins
Outcomes

PICO 10.15

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (high risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus statins and ezetimibe
Comparator
Statins and ezetimibe
Outcomes

PICO 10.16

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (high risk)
Intervention
Ezetimibe
Comparator
No lipid-lowering drug
Outcomes

PICO 10.17

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (high risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors
Comparator
No lipid-lowering drug
Outcomes

PICO 10.18

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (high risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors
Comparator
Ezetimibe
Outcomes

PICO 10.19

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (high risk)
Intervention
Ezetimibe and PCSK9 inhibitors
Comparator
PCSK9 inhibitors
Outcomes

PICO 10.20

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (high risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus ezetimibe
Comparator
Ezetimibe
Outcomes

PICO 10.21

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (moderate risk)
Intervention
Ezetimibe plus statins
Comparator
Statins
Outcomes

PICO 10.22

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (moderate risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus statins
Comparator
Statins
Outcomes

PICO 10.23

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (moderate risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus statins
Comparator
Ezetimibe plus statins
Outcomes

PICO 10.24

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (moderate risk)
Intervention
Ezetimibe and PCSK9 and statins
Comparator
PCSK9 and statins
Outcomes

PICO 10.25

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (moderate risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus statins and ezetimibe
Comparator
Statins and ezetimibe
Outcomes

PICO 10.26

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (moderate risk)
Intervention
Ezetimibe
Comparator
No lipid-lowering drug
Outcomes

PICO 10.27

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (moderate risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors
Comparator
No lipid-lowering drug
Outcomes

PICO 10.28

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (moderate risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors
Comparator
Ezetimibe
Outcomes

PICO 10.29

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (moderate risk)
Intervention
Ezetimibe and PCSK9 inhibitors
Comparator
PCSK9 inhibitors
Outcomes

PICO 10.30

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (moderate risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus ezetimibe
Comparator
Ezetimibe
Outcomes

PICO 10.31

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (low risk)
Intervention
Ezetimibe plus statins
Comparator
Statins
Outcomes

PICO 10.32

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (low risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus statins
Comparator
Statins
Outcomes

PICO 10.33

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (low risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus statins
Comparator
Ezetimibe plus statins
Outcomes

PICO 10.34

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (low risk)
Intervention
Ezetimibe adding to PCSK9 and statins
Comparator
PCSK9 and statins
Outcomes

PICO 10.35

Population
Adults in primary prevention receiving high dose statins and considering further CV risk reduction (low risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus statins and ezetimibe
Comparator
Statins and ezetimibe
Outcomes

PICO 10.36

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (low risk)
Intervention
Ezetimibe
Comparator
No lipid-lowering drug
Outcomes

PICO 10.37

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (low risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors
Comparator
No lipid-lowering drug
Outcomes

PICO 10.38

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (low risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors
Comparator
Ezetimibe
Outcomes

PICO 10.39

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (low risk)
Intervention
Ezetimibe and PCSK9 inhibitors
Comparator
PCSK9 inhibitors
Outcomes

PICO 10.40

Population
Adults in primary prevention intolerant to statins and considering further CV risk reduction (low risk)
Intervention
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors plus ezetimibe
Comparator
Ezetimibe
Outcomes

PICO 10.41

Population
Adults at cardiovascular risks
Intervention
PCSK9 inhibitors
Comparator
Standard care or other lipid-lowering agents
Outcomes

PICO 10.42

Population
Adults at cardiovascular risks
Intervention
Ezetimibe
Comparator
Standard care or other lipid-lowering agents
Outcomes

PICO 30.1

Population
Adults with cardiovascular risks
Intervention
PCSK9 inhibitors
Comparator
Control
Outcomes

PICO 30.2

Population
Adults with cardiovascular risks
Intervention
Ezetimibe
Comparator
Control
Outcomes